FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus; Guidance for Industry” was released on October 2, 2019 and recommends that CTS modify our current HCV reflex testing algorithm to support these best practices. The new algorithm will take effect on April 20, 2020.
Check out the Communication page for the complete details by clicking the link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...